case | 03 Dec 2021
Setterwalls has advised Alligator Bioscience in connection with rights issue of approximately SEK 257 million
![Responsive image](https://setterwalls.se/wp-content/uploads/2021/12/Life-Science-microscope.jpg-1200x500.png)
Setterwalls has advised Alligator Bioscience AB (“Alligator”), listed on Nasdaq Stockholm, in connection with a rights issue of shares of approximately SEK 257 million. The rights issue was subscribed to approximately 121 per cent.
Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s shares are listed on Nasdaq Stockholm, and the company is headquartered in Lund, Sweden.
Contact:
Practice areas: